Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes

Int J Antimicrob Agents. 2018 Mar;51(3):498-502. doi: 10.1016/j.ijantimicag.2017.11.003. Epub 2017 Nov 20.

Abstract

Infections due to multidrug-resistant bacteria (MDR) are currently a clinical challenge, mainly in elderly patients. The antimicrobial spectrum, safety and efficacy of ceftolozane/tazobactam (C/T) make it an attractive option for the treatment of MDR bacterial infections beyond the indications approved to date. Here we report our experience with C/T in four cases of osteomyelitis and three cases of skin and soft-tissue infections due to extensively-drug-resistant Pseudomonas aeruginosa.

Keywords: Ceftolozane/tazobactam; Multidrug resistance; Osteomyelitis; Pseudomonas aeruginosa; Skin and soft-tissue infection.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use*
  • Cephalosporins / therapeutic use*
  • Drug Resistance, Multiple, Bacterial
  • Female
  • Humans
  • Male
  • Middle Aged
  • Osteomyelitis / drug therapy*
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / therapeutic use
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / isolation & purification
  • Retrospective Studies
  • Skin Diseases, Bacterial / drug therapy*
  • Soft Tissue Infections / drug therapy*
  • Tazobactam
  • Treatment Outcome
  • beta-Lactamase Inhibitors / therapeutic use*

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • beta-Lactamase Inhibitors
  • ceftolozane, tazobactam drug combination
  • Penicillanic Acid
  • Tazobactam